PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
Status:
Completed
Trial end date:
2018-01-04
Target enrollment:
Participant gender:
Summary
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the
regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal
triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure
will be percent change in central subfield thickness as measured by OCT at 8 weeks.
Participants will continue in the study for 24 weeks in order to evaluate relative effects of
the 3 treatment strategies on the duration of treatment effects, requirement for additional
injections, and adverse effects.
Note: The planned sample size for the POINT Trial was 267 subjects. On 17 July 2017, with 192
subjects enrolled, the Data and Safety Monitoring Committee (DSMC) reviewed the planned
interim analysis and recommended that the goals of the trial could be accomplished by
completing follow-up of enrolled subjects without the recruitment of additional subjects. Per
the DSMC recommendations, recruitment was suspended and follow-up of enrolled subjects was
completed according to the protocol.